Rebondas, Julie Ann T.

HRN: 20-37-93  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/20/2022
CEFUROXIME 1.5GM (VIAL)
05/20/2022
05/20/2022
IV
1.5g
LD
Lacerated Wound Sec To Straddle Injury; For OR
Waiting Final Action 
05/21/2022
CEFUROXIME 500MG (TAB)
05/21/2022
05/28/2022
ORAL
500mg
Q12
Post Vaginal Exploration And Repair Of Laceration
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: